Portfolio News
Sofinnova Capital
Avantium reaches key commercial milestone for its FDCA flagship plant with commitments for >50% of its output
Avantium N.V., a leading technology company in renewable chemistry, announces that it has signed a conditional offtake agreement with Resilux, an international rigid plastic packaging supplier, for the supply of PEF resin from the planned Avantium FDCA flagship plant. This brings the total of such offtake contracts to five.
Related Strategy
Industrial BiotechRelated Company
AvantiumAMSTERDAM, 7 April 2021, 18:00 hrs CEST – Avantium N.V., a leading technology company in renewable chemistry, announces that it has signed a conditional offtake agreement with Resilux, an international rigid plastic packaging supplier, for the supply of PEF resin from the planned Avantium FDCA flagship plant. This brings the total of such offtake contracts to five.
The planned FDCA flagship plant is set to produce 5 kilotonnes of FDCA (furandicarboxylic acid) per annum, the key building block for the 100% fossil-free, recyclable polymer PEF (polyethylene furanoate). Including an additional commitment from one of the previously announced offtake partners, the five conditional offtake agreements represent a total offtake volume of over 50% of the FDCA production capacity from the flagship plant. This marks an important step towards a positive Final Investment Decision (FID) for the construction of the world’s first commercial FDCA plant, which Avantium would plan to open in 2023.
Related News
Signadori Bio appoints Dr. Selwyn Ho, MB BS as Chief Executive Officer to lead company into next stage of growth
Abivax announces full year 2025 financial results and provides business updates
Sensorion reports six-month update from the Audiogene Phase 1/2 Trial of SENS-501 and advances GJB2-GT (SENS-601) toward first-in-human clinical development
Elevara Medicines doses first patient in Phase 2b START-SYNERGY trial of ELV001 in rheumatoid arthritis patients with incomplete response to TNFi
May Health raises $11.7M to advance its novel technology to treat PCOS-related infertility